By Fineline Cube 
Shanghai-based medical robotics developer Operation Robot Co., Ltd. has reportedly raised close to RMB 100 million (USD 13.7 million) in a Series C financing round. The funding was co-led by Jinan Medical Center and Jinan Huaiyin District Guorong Holdings, with participation from Sunland Fund. The proceeds will be used to advance the research and development (R&D), mass production, and commercialization of its AI-driven endovascular intervention surgical robot.
Company Background and Product Development
Founded in 2017 in Shanghai Zhangjiang, Operation Robot has made significant progress in the field of vascular intervention surgical robotics. The company has completed a multi-center clinical study for its vascular intervention surgical robot in coronary percutaneous coronary intervention (PCI) and has initiated market filing for the product in China. This milestone positions the company at the forefront of innovation in AI-driven surgical solutions.
Funding and Future Outlook
The Series C funding underscores the confidence of investors in Operation Robot’s technological capabilities and market potential. With this new capital, the company is poised to accelerate the development and deployment of its cutting-edge surgical robots, enhancing the precision and efficiency of endovascular interventions.-Fineline Info & Tech